Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Carol E. Koro"'
Autor:
Tongtong Wang, Shrita M. Patel, Anne Hickman, Xinyue Liu, Philip LStJ Jones, Ira Gantz, Carol E. Koro
Publikováno v:
Diabetes Therapy, Vol 11, Iss 3, Pp 711-723 (2020)
Abstract Introduction Based on post-marketing surveillance, concern has been raised that sodium–glucose cotransporter 2 inhibitors (SGLT2i) may increase the risk of necrotizing fasciitis of the perineum (Fournier’s gangrene, FG). As a result of t
Externí odkaz:
https://doaj.org/article/57a78bad45474da09e6cb960c8bf56c0
Autor:
Janet Pientka, Veronica Bainbridge, Monika Stender, Annette Stemhagen, Natalie O'Donnell, Carol E. Koro
Publikováno v:
Drugs-Real World Outcomes
Background The risk of pancreatitis and potential risk of medullary thyroid carcinoma associated with glucagon-like peptide-1 receptor agonists prompted the US Food and Drug Administration to require a Risk Evaluation and Mitigation Strategy for albi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78c11f93b6182c105684addab96cb2a1
https://doi.org/10.1007/s40801-017-0128-3
https://doi.org/10.1007/s40801-017-0128-3
Publikováno v:
Diabetesmetabolic syndrome. 13(1)
Aim Data on prevalence of chronic kidney disease (CKD) among US adults with type 2 diabetes (T2D) and cardiovascular diseases (CVD) are limited. The aim of this study was to provide such estimates for T2D, both overall and in those with CVD. Material
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a6a32d3f1a89b30cad3556fdd7ace2b
https://pubmed.ncbi.nlm.nih.gov/30641775
https://pubmed.ncbi.nlm.nih.gov/30641775
Publikováno v:
Diabetes. 67
Data on the prevalence of CKD among U.S. adults with T2D and CVD are limited. The aim of this study was to provide such estimates for T2D, both overall and in those with CVD. Using the NHANES 2007-2014 data, we conducted a cross-sectional analysis of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97d4c7582b4001610d1907254f14f071
https://doi.org/10.2337/db18-2381-pub
https://doi.org/10.2337/db18-2381-pub
Publikováno v:
Diabetes. 67
Overall prevalence of CKD in the U.S. adult general population was estimated to be 14.8%. But data on the prevalence of CKD among CVD population are limited. Using the NHANES 2007-2014 data, we conducted a cross-sectional analysis of an adult sample
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::378c9e073924728b2806a553cf80869b
https://doi.org/10.2337/db18-1618-p
https://doi.org/10.2337/db18-1618-p
Autor:
Gloria C. Chi, Nancy S. Jenny, Annette L. Fitzpatrick, Carol E. Koro, Mary Cushman, Michael C. Irizarry
Publikováno v:
Atherosclerosis. 235:384-391
To evaluate associations between Lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity with risk of dementia and its subtypes.Analysis were completed on 3320 participants of the Cardiovascular Health Study (CHS), a population-based long
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f48a3e72e833900de23a5130fbc5226
https://doi.org/10.1016/j.atherosclerosis.2014.04.032
https://doi.org/10.1016/j.atherosclerosis.2014.04.032
Publikováno v:
Clinical Trials. 10:20-31
Background Meta-analyses of clinical trial safety data have risen in importance beyond regulatory submissions. During drug development, sponsors need to recognize safety signals early and adjust the development program accordingly, so as to facilitat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5454326a2c9ab9058c2bb50037e9ece
https://doi.org/10.1177/1740774512465495
https://doi.org/10.1177/1740774512465495
Publikováno v:
Atherosclerosis. 225:11-21
Background Lipoprotein association phospholipase A2 (Lp-PLA 2 ), an enzyme which has been found in atherosclerotic plaque is currently under investigation in large Phase III clinical trials of vascular disease prevention. We assessed in a variety of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41146cc25f2f64aebe5618ca1a2dcc32
https://doi.org/10.1016/j.atherosclerosis.2012.06.020
https://doi.org/10.1016/j.atherosclerosis.2012.06.020
Autor:
Ronit Katz, Ruth F. Dubin, Annette L. Fitzpatrick, Joachim H. Ix, Bryan Kestenbaum, Nancy S. Jenny, Ian DeBoer, Carmen A. Peralta, Mary Cushman, Michael G. Shlipak, Carol E. Koro, Mark J. Sarnak
Publikováno v:
American Journal of Nephrology. 34:512-518
Background: Whether lipoprotein-associated phospholipase A2 (Lp-PLA2) levels are associated with kidney function decline has not been well studied. Methods: We investigated associations of Lp-PLA2 antigen and activity with kidney function decline and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6102023660890abf55aef9a4b1e92643
https://doi.org/10.1159/000333045
https://doi.org/10.1159/000333045
Publikováno v:
Clinical Therapeutics. 31:2608-2617
The aims of this study were to estimate the proportion of patients with type 2 diabetes mellitus (DM) in the United States with different stages of chronic kidney disease (CKD) and to describe glycemic control and antidiabetic drug use among them.Usi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32d2d136ac536c8162713e63c8ba768b
https://doi.org/10.1016/j.clinthera.2009.10.020
https://doi.org/10.1016/j.clinthera.2009.10.020